Seven days of statin treatment improves nitric-oxide mediated endothelial-dependent cutaneous microvascular function in women with endometriosis.
Endometriosis
Microvascular function
Nitric oxide
Women's health
Journal
Microvascular research
ISSN: 1095-9319
Titre abrégé: Microvasc Res
Pays: United States
ID NLM: 0165035
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
28
04
2022
revised:
26
07
2022
accepted:
09
08
2022
pubmed:
16
8
2022
medline:
14
9
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
Endometriosis is associated with systemic inflammation and increased risk of cardiovascular disease (CVD). Endothelial dysfunction is one of the first manifestations of CVD but is unexplored in women with endometriosis. HMG-CoA-reductase inhibitors (statins) exert potent anti-inflammatory effects, and have been proposed as an adjunctive therapy in women with endometriosis. We hypothesized that microvascular endothelial function would be impaired in otherwise healthy women with endometriosis mediated by reduced nitric oxide (NO)-dependent dilation and that short term statin administration would improve endothelial function. In 8 healthy control (HC: 33 ± 9 yr) and 8 women with endometriosis (EN: 34 ± 9 yr), laser-Doppler flux (LDF) was measured continuously during graded intradermal microdialysis perfusion of the endothelium-dependent agonist acetylcholine (Ach: 10 Ach-induced vasodilation was blunted in women with endometriosis (main effect p < 0.01), indicating impaired endothelial function. NO-dependent vasodilation was also reduced in women with endometriosis (HC: 217 ± 120.3 AUC vs. EN: 88 ± 97 AUC, p = 0.03). Oral atorvastatin improved Ach-induced (main effect p < 0.01) and NO-dependent (295 ± 153 AUC; p = 0.05) vasodilation in women with endometriosis. Microcirculatory endothelium-dependent vasodilation is impaired in women with endometriosis, mediated in part by reductions in NO. Short-term oral atorvastatin improved endothelium-dependent vasodilation, suggesting that statin therapy may be a viable intervention strategy to mitigate accelerated CVD risk in women with endometriosis.
Identifiants
pubmed: 35970408
pii: S0026-2862(22)00111-X
doi: 10.1016/j.mvr.2022.104421
pmc: PMC9527706
mid: NIHMS1835239
pii:
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Nitric Oxide
31C4KY9ESH
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
104421Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL161000
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG049676
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.
Références
J Appl Physiol (1985). 2020 Nov 1;129(5):1117-1119
pubmed: 32702274
J Appl Physiol (1985). 2007 Mar;102(3):890-5
pubmed: 17110511
J Chin Med Assoc. 2016 Nov;79(11):577-582
pubmed: 27553580
Hum Reprod. 2012 May;27(5):1320-6
pubmed: 22416009
Circulation. 2018 Oct 23;138(17):e426-e483
pubmed: 30354655
Am J Physiol Heart Circ Physiol. 2021 Oct 1;321(4):H728-H734
pubmed: 34477463
Biochem Biophys Res Commun. 2001 Dec 14;289(4):857-61
pubmed: 11735125
Am J Physiol Heart Circ Physiol. 2022 Feb 1;322(2):H319-H327
pubmed: 34995164
Am J Physiol Regul Integr Comp Physiol. 2011 Sep;301(3):R763-8
pubmed: 21715698
J Minim Invasive Gynecol. 2019 Jul - Aug;26(5):781-784
pubmed: 31028947
Reprod Sci. 2019 Oct;26(10):1343-1350
pubmed: 29587611
Hypertension. 2017 Jul;70(1):59-65
pubmed: 28559401
Mol Pharmacol. 2012 Aug;82(2):246-54
pubmed: 22570368
Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H2-12
pubmed: 20952670
Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43
pubmed: 15198965
Menopause. 2006 Nov-Dec;13(6):951-8
pubmed: 16977254
Gynecol Obstet Invest. 2006;62(3):139-47
pubmed: 16679772
Hypertension. 2011 Nov;58(5):935-42
pubmed: 21931069
Am J Physiol Heart Circ Physiol. 2020 Oct 1;319(4):H906-H914
pubmed: 32857616
Cardiovasc Res. 2006 Jan;69(1):36-45
pubmed: 16324688
Reprod Sci. 2017 Mar;24(3):376-381
pubmed: 27655771
J Appl Physiol (1985). 2017 Nov 1;123(5):1024-1038
pubmed: 28729391
Med Sci Monit. 2013 Jul 05;19:534-9
pubmed: 23828228
Curr Atheroscler Rep. 2021 Dec 1;23(12):80
pubmed: 34851454
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1090-6
pubmed: 17483240
Hypertension. 2005 Jun;45(6):1107-12
pubmed: 15867135
Heart. 2018 Jan;104(2):127-134
pubmed: 28663361
Cell Cycle. 2015;14(10):1583-95
pubmed: 25950192
J Clin Endocrinol Metab. 2018 Jan 1;103(1):64-74
pubmed: 29040578
Biol Reprod. 2017 Jul 1;97(1):32-38
pubmed: 28637327
Semin Reprod Med. 2017 May;35(3):263-270
pubmed: 28658710
Hum Reprod. 2014 Jun;29(6):1205-10
pubmed: 24777848
Am J Epidemiol. 2004 Oct 15;160(8):784-96
pubmed: 15466501
J Physiol. 2011 Apr 15;589(Pt 8):2093-103
pubmed: 21486801
Fertil Steril. 2016 Oct;106(5):1011-1017
pubmed: 27521769
Hypertension. 2017 May;69(5):902-909
pubmed: 28348008
Fertil Steril. 2012 Sep;98(3):511-9
pubmed: 22819144
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6301-11
pubmed: 26261506
Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H539-H546
pubmed: 32734817
N Engl J Med. 2009 Jan 15;360(3):268-79
pubmed: 19144942
Biorheology. 2013;50(5-6):241-55
pubmed: 24398607
Rev Assoc Med Bras (1992). 2015 Nov-Dec;61(6):519-23
pubmed: 26841161
Hum Reprod Update. 2010 Nov-Dec;16(6):651-74
pubmed: 20462942
J Physiol. 2011 Oct 1;589(Pt 19):4787-97
pubmed: 21807618
Circ Res. 2019 Feb 15;124(4):564-574
pubmed: 30582458
Eur J Clin Invest. 2005 Jan;35(1):47-51
pubmed: 15638819